Peptides & Compounding: USP <795> & <797> Compliance

The increasing popularity of peptides – short chains of amino acids used therapeutically for conditions ranging from diabetes to obesity – is bringing greater scrutiny to compounding pharmacies. As these treatments move from the realm of innovation to more widespread use, adherence to United States Pharmacopeia (USP) standards, specifically <795> for nonsterile compounding and <797> for sterile compounding, is becoming paramount. Regulatory bodies and legal precedents are increasingly referencing these USP chapters to assess professional conduct, highlighting a shift towards stricter enforcement.

What Defines a Peptide, and Why Does it Matter?

Peptides are composed of less than 40 amino acids. Once that threshold is crossed, the substance is classified as a biologic, subject to a different, more rigorous regulatory pathway. Crucially, pharmacies generally cannot obtain a ‘biologics license’ required to compound biologics. This distinction is fundamental. According to the 2019 Biologics Price Competition and Innovation Act, incredibly few peptides are currently eligible for compounding.

So, which peptides can be compounded? The criteria are specific: a peptide must be FDA-approved, have FDA Generally Recognized as Safe (GRAS) status, possess a USP monograph (a publicly available standard for quality, strength, identity, and purity), appear on the 503A Bulks List, or be categorized as Category I on the interim 503A Bulks List. Examples include NAD+ and sermorelin. Frier Levitt, a law firm specializing in pharmaceutical regulation, details these categories, emphasizing the importance of verifying a peptide’s status before compounding.

The Role of USP Standards in Peptide Compounding

USP standards <795> and <797> provide detailed guidelines for compounding pharmacies. <795> focuses on nonsterile compounding – preparing medications without the need for sterilization – while <797> addresses sterile compounding, essential for injectable medications. Recent revisions to these chapters are placing increased emphasis on documentation, ingredient verification, hygiene, and accurate record-keeping. The Pharmacy Times reports that nonsterile compounding frequently falls short in areas like beyond-use dating (how long a compounded medication remains safe and effective), ingredient verification, and maintaining records that accurately reflect actual practices.

Beyond adherence to these standards, sourcing Active Pharmaceutical Ingredients (APIs) is critical. Any supplier must be registered with the FDA as an API manufacturer and provide a Certificate of Analysis, confirming the API’s quality and purity. APIs labeled ‘research use only’ (RUO) are explicitly prohibited for use in human or veterinary compounding. For human use, the API must be ‘pharmaceutical grade,’ not ‘food grade’ or ‘RUO.’

Enforcement and Safety Concerns

The FDA is actively monitoring the market and taking action against sites selling peptides over-the-counter (OTC) with disclaimers that they are “RUO” and not intended for diagnosis, treatment, cure, or prevention of any disease. This practice is a clear violation of regulations. The agency has a listing of ingredients, including peptides, that present safety issues and should not be compounded.

The rise in readily available peptides online raises concerns about quality control and potential harm to patients. Compounding pharmacies operating outside of established USP guidelines and regulatory frameworks risk producing medications that are ineffective, contaminated, or contain incorrect dosages.

USP Resources for Peptide Solutions

Recognizing the complexities surrounding peptide compounding, the United States Pharmacopeia (USP) offers comprehensive solutions. USP provides documentary standards with validated test methods and acceptance criteria, helping developers and compounders navigate the regulatory landscape. These resources are vital for ensuring the quality and safety of peptide medications.

What to Expect in the Future

The regulatory landscape for peptide compounding is likely to continue evolving. Increased enforcement of USP standards, coupled with ongoing FDA scrutiny, will likely lead to greater accountability for compounding pharmacies. Further clarification of the 503A Bulks List and the development of additional USP monographs for peptides are also anticipated.

For patients considering peptide therapy, it is essential to consult with a qualified healthcare professional and ensure that any compounded medications are sourced from a pharmacy that adheres to the highest quality standards and complies with all applicable regulations. Staying informed about the latest guidance from the FDA and USP is also crucial for both patients and healthcare providers.